Allergan has received approval from the U.S. Food and Drug Administration (FDA) to market Natrelle Inspira SoftTouch breast implants, a new medium firmness, cohesive gel option for women undergoing breast reconstruction, augmentation or revision surgery.
“Now, the Inspira line of breast implants helps physicians to better meet diverse, patient-specific needs based on available breast tissue and desired outcomes. We’re delighted to have this offering available in the U.S. since they are so popular with doctors and patients internationally,” said David Nicholson, chief R&D officer of Allergan.
